POMDOCTOR Ltd (POM) has commenced termination of its American Depositary Receipt program and related deposit agreement, with termination expected before market opening on October 21, 2026. The company plans to list Class A ordinary shares directly on Nasdaq in place of the ADSs, with trading expected to begin that day under POM.
At the same time as the termination, the company will consolidate each class of ordinary shares at a 10-for-1 ratio. In the mandatory exchange, every 10 ADSs will be exchanged for 3 post-consolidation Class A ordinary shares. The board approved the actions on September 3, 2026, and shareholders approved them on a non-binding advisory basis on September 30, 2026.
POM received a Nasdaq staff determination that its ADS closing bid had remained below $1.00 per share for 30 consecutive business days, from August 24, 2026, through October 5, 2026, and that it did not meet the minimum bid-price requirement. Because POM effected a 1-for-18 reverse stock split on June 22, 2026, Nasdaq said it was ineligible for the usual 180-calendar-day compliance period and determined to delist its securities from the Nasdaq Global Market.
POM intends to request a hearing by October 13, 2026, and present a plan to regain compliance. Unless POM timely requests a hearing, its securities will be suspended from trading at the opening of business on October 15, 2026. A timely request stays the suspension and Form 25-NSE filing while the appeal is pending. POM said it is evaluating alternatives and that there can be no assurance it will regain compliance or succeed on appeal.
POMDOCTOR Limited shareholders approved a 10-to-1 consolidation of issued and unissued share capital. The resolution provides that it will take effect simultaneously with termination of the American Depositary Receipt program and the direct listing of Class A ordinary shares on The Nasdaq Stock Market. It also amends the authorized share count from 500,000,000 shares to 50,000,000 shares.
Shareholders separately approved ADR termination and the direct listing on a non-binding advisory basis. The reported vote totals were 45,387,346 votes for the consolidation and 45,395,656 for the advisory proposal; the totals are calculated by voting power and exclude 7,639,947 discretionary proxies separately reported by the Inspector of Election. The resolution provides that fractional shares will be aggregated and rounded up to the nearest whole share at the participant level.
POMDOCTOR Ltd (POM) reported progress in developing and commercializing its AI-enabled chronic disease management ecosystem, including completed multiple rounds of system optimization, expanded real-world data (RWD) applications and ongoing in-hospital and out-of-hospital care pilots. Its product roadmap includes risk identification, personalized interventions and physician-patient follow-up workflows. The company says patient-management data can be processed to refine AI models and support physicians in assessing health trends and developing personalized management strategies.
RWD initiatives include pharmaceutical real-world studies, research cooperation, B2B healthcare data services and collaborations with third-party healthcare institutions. The pilots are designed to extend care beyond individual clinical encounters through ongoing monitoring, physician follow-up, medication management and personalized intervention. The company describes its future development and commercialization plans as forward-looking statements and cautions that actual results may differ materially.
POMDOCTOR Limited (POM) reported unaudited results for the six months ended June 30, 2026. Revenue was RMB 185,000,259, versus RMB 174,469,851 a year earlier; gross profit was RMB 25,273,527 versus RMB 28,317,401. Operating expenses were RMB 258,606,653, and operating loss was RMB 233,333,126 versus RMB 13,460,030. Net loss was RMB 238,170,188 versus RMB 19,885,492.
Operating cash flow was RMB 10,076,600 provided, compared with RMB 14,987,658 used in 2025; cash and cash equivalents were RMB 12,605,976 at June 30, 2026. The Group reported a RMB 137.2 million working-capital deficit and said cash and revenue could not be projected to cover operating expenses and obligations for the next 12 months after the statements were available to be issued, raising substantial doubt about its ability to continue as a going concern. Its plans included a RMB 6.0 million loan obtained on August 3, 2026, and RMB 2.1 million in loans from Li Xu; management said there was no assurance these plans would be sufficient.
POMDOCTOR Ltd highlighted a “hardware + AI + payment” healthcare model intended to bring continuous health monitoring, AI-powered analysis, physician intervention, healthcare payment and fulfillment together. The company says it aims to develop predictive healthcare infrastructure across the patient journey, beyond platforms focused on individual services such as online consultations or prescription processing.
POMDOCTOR described its existing healthcare platform and physician network as a foundation for developing predictive healthcare data and services. The company says its future performance should increasingly be assessed through a digital healthcare technology infrastructure lens, considering proprietary hardware, AI-driven data assets, clinical services and payment connectivity.
POMDOCTOR Ltd (POM), a digital healthcare company focused on AI-enabled and predictive healthcare, reported multi‑year growth and outlined a global expansion plan while announcing participation in H.C. Wainwright’s 28th Annual Global Investment Conference. A virtual presentation will be available beginning September 11, 2026, and management will hold one‑on‑one investor meetings during the September 14‑16, 2026 event.
Net revenues rose from RMB 304.9 million in FY2023 to RMB 399.9 million in FY2025, and gross profit increased to RMB 130.9 million with a 13.9% gross margin, while the company remained loss‑making with FY2025 net loss of RMB 52.3 million212,800, more than 699,338 paying patients and over 3.13 million prescriptions processed. POMDOCTOR presents a roadmap centered on building a predictive healthcare data and services infrastructure, a US$30 million capital‑raising plan primarily for U.S. market entry and AI/data infrastructure, and a phased global rollout beginning with a U.S. launch at CES 2027.
POMDOCTOR Ltd (POM) has called an extraordinary general meeting for September 30, 2026 to seek shareholder approval for terminating its American Depositary Receipt (ADR) program and moving to a direct listing of its Class A ordinary shares on Nasdaq. The ADR termination and direct listing are intended to occur on the same date and are presented as an advisory, non-binding resolution.
Shareholders are also being asked to approve a 10‑to‑1 Share Consolidation of all share classes, changing par value from US$0.0001 to US$0.001 per share and reducing authorized share capital from 500,000,000 to 50,000,000 shares while keeping total authorized capital at US$50,000. No fractional shares will be issued; any fractions will be rounded up to the nearest whole share at the participant level. As of the September 2, 2026 record date, 27,802,964 ordinary shares were outstanding, consisting of 25,760,922 Class A shares with one vote each and 2,042,042 Class B shares with twenty votes each. A third proposal would allow adjournment of the meeting to solicit additional proxies if needed.
POMDOCTOR Ltd (POM), a China-based digital healthcare company focused on AI-enabled solutions, announced it has formally begun preparations to enter the U.S. market as part of its global growth strategy. The company is recruiting U.S.-based leadership and operational staff, has completed an initial assessment of the U.S. healthcare market, and is building a local compliance and regulatory framework.
POMDOCTOR is also localizing its products and holding exploratory discussions with potential U.S. partners. The expansion will follow a multi-phase approach starting with pilot validation, including potential use cases in remote patient monitoring and chronic disease management, followed by deeper engagement with payers and providers and, if successful, progressive commercial scaling across selected U.S. regions.
POMDOCTOR LIMITED, a digital healthcare company focused on AI-enabled and predictive healthcare solutions, describes its healthcare intelligence flywheel, a closed-loop model integrating wearable devices, healthcare data, AI analytics, physician services, and insurance payment networks. The model is intended to let each service cycle generate additional data, strengthen AI capabilities, and improve service personalization and user engagement.
The company explains that repeated healthcare service cycles are designed to deepen and diversify real-world healthcare data, enhance individualized risk assessment and recommendations, and improve user retention. Management states that the company’s competitive position relies on orchestrating data collection, AI analysis, professional medical services, pharmaceutical fulfillment, and payment networks into a unified ecosystem that becomes harder to replicate over time.